Take a look at the finalists for the Pride of Cumbria NHS Worker of the Year award
The award, which is sponsored by NRL, is set to highlight those who 'show bravery, courage and resilience in their day-to-day work, demonstrated by outstanding acts of kindness and compassion to families and patients'.
The Pride of Cumbria Awards 2025 will be held on Wednesday, June 18 at the Greenhill Hotel, Wigton.
Sylvie Booth
Sylvie Booth (Image: Supplied) Orthoptist Sylvie works within the North Cumbria Integrated Care Trust, going 'above and beyond under very challenging working conditions'.
Her nominator said: "The gift of sight through the services Sylvie provides, gives those with sight impairment or changes in sight following events like stroke, is life changing in terms of individual safety, sense of self worth, ability to access rehab (e.g. learning to read or walk again), returning to work and living a quality and meaningful life.
"Sylvie very much deserves to be recognised for this."
Laura Street
Laura Street (Image: Supplied) Laura works as the improvement lead for cancer at the North Cumbria Integrated Care Trust, and is said to have an 'unwavering dedication' to her role.
Her nominator said: "Laura has been fundamental to some massive improvements in Cancer care at North Cumbria this year, and she is exceptionally dedicated to ensuring that every patient gets timely, efficient and compassionate care on their cancer journey.
"Laura shows tremendous resilience, courage and compassion to patients and their families, and is unwaveringly dedicate to ensuring that the local population has access to the best cancer care possible."
Valerie Coltart
Valerie Coltart (Image: Supplied) Valerie works as an NHS dietician at the Cumberland Infirmary being nominated by the parent of one of her patients for 'always going the extra mile' in her work.
Her nominator said: "Valerie comes for home visits when my child is having a bad day so he doesn't miss an appointment, she also organises if there is a slip up with his feeds and medication and she will bring things to us if needed on her way home from collecting her own children, she is the nicest person too, and deserves to be recognised."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
First new treatment for advanced bladder cancer in decades given green light
A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
Yahoo
3 hours ago
- Yahoo
NHS says eight services need to be paid for with millions warned
The NHS has warned eight things UK households may have to pay for with millions warned. The NHS says although most NHS treatment is free, there is usually a charge for eight items. This includes NHS prescriptions, NHS dental check-ups and treatment and sight tests as well as new glasses or contact lenses, repairing or replacing glasses or contact lenses, NHS wigs and NHS fabric supports – things like surgical bras, support tights and spinal supports. The list is completed by travel for NHS treatment. The NHS advises: "You could be entitled to help with these costs depending on your circumstances. It should take about 3 minutes to check." READ MORE: Lloyds Bank announces start date of new £300 rule with customers warned READ MORE: Pub-goers in England face 'insidious' and 'stealth' new rule at the bar READ MORE Hobbycraft shutting 9 of 115 stores with full list announced The health body adds: "We use your date of birth to work out your age. Depending on where you live, your age could entitle you to help with NHS costs, such as free prescriptions or dental treatment." Speaking previously over NHS prescription charges being frozen, Labour Party MP Secretary of State for Health and Social Care, Wes Streeting, said: "This government's Plan for Change will always put working people first, and our moves today to freeze prescription charges will put money back into the pockets of millions of patients. "Fixing our NHS will be a long road - but by working closer with our pharmacies we're saving money and shifting care to the community where it's closer to your home. "We made the difficult but necessary choices at the budget to fund moves like this and change our NHS so it can once again be there for you when you need it." Around 89% of prescriptions in England are already dispensed free of charge to children, the over 60s, pregnant women and those with certain medical conditions. This freeze will not impact that scheme. In addition to the freeze on charges, the NHS Low Income Scheme offers help with prescription payments, with free prescriptions for eligible people in certain groups such as pensioners, students and those who receive state benefits or live in care homes.
Business Wire
11 hours ago
- Business Wire
ieso Sharpens Focus on AI-Powered Mental Healthcare with Sale of UK Telecare Services Business
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- ieso, a global leader in evidence-based digital mental health, today announced the sale of its UK telecare services business to Mindler, a leading pan-European digital therapy provider. The acquisition is specific to ieso's NHS-facing care operations in the UK, including delivery of typed and video therapy services. Mindler's press release is available here. "As AI adoption accelerates, mental health is emerging as one of its most urgent and natural use cases. The market is moving fast, and so are we." - Kent Tangen, CEO, ieso Share The parent company, ieso Digital Health Limited, remains fully independent and continues to operate under the ieso brand. With the sale now complete, ieso is entirely focused on scaling its clinical-grade generative AI platform, Velora, to deliver safe, effective, personalized mental health support via SaaS integration into clinical workflows. 'We're proud to have supported thousands of lives through ieso's UK telecare services. That legacy will always be a part of who we are,' said Kent Tangen, CEO at ieso. 'With those operations now in excellent hands at Mindler, ieso is committed to building the future we've long envisioned: delivering safe, effective AI-powered mental healthcare at scale. Our immediate focus is in the US, but our mission is global. As AI adoption accelerates, mental health is emerging as one of its most urgent and natural use cases. The market is moving fast, and so are we.' ieso was advised on the transaction by Cooley LLP and Artis Finance. About ieso ieso is a pioneer in AI-powered mental healthcare, combining clinical expertise with advanced technology to help more people feel better, faster. Its latest product, Velora, is a next-generation generative AI-based program that delivers outcomes on par with human-delivered care and is designed to integrate seamlessly into existing clinical workflows. Backed by over a decade of research and real-world data, ieso is focused on increasing access to safe, effective, and scalable mental health support in the US and beyond. To learn more or request a demo, visit
